Durect shares are trading lower after the company announced results from its Phase 2B AHFIRM trial did not achieve statistical significance for either dose on the primary endpoint of mortality or transplant at 90 days.
Portfolio Pulse from Benzinga Newsdesk
Durect Corporation's shares are trading lower after the company announced that its Phase 2B AHFIRM trial did not achieve statistical significance for either dose on the primary endpoint of mortality or transplant at 90 days.
November 08, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Durect's stock price is expected to decrease in the short term due to the failure of its Phase 2B AHFIRM trial to meet its primary endpoint.
The failure of a clinical trial often leads to a decrease in the stock price of a pharmaceutical company. In this case, Durect's Phase 2B AHFIRM trial did not meet its primary endpoint, which is likely to negatively impact investor sentiment and lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100